Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients in acute sciatica

References

1. • Frymoyer JW
   Back pain and sciatica.
   NEJM. 1988; 318: 291-300
   • Scopus (939)
   • PubMed
   • Crossref
   • Google Scholar
2. • Rosa A
   • Delcour J
   Mononeuropathies: Névralgie cervicobrachiale, névralgie sciatique. Etiologie, diagnostique, traitement.
   Rev Prat. 1991; 41: 275-277
   • PubMed
   • Google Scholar

3. Narjes H, Bluhmki E, Huskisson EC. Efficacy and tolerance of UHAC-62 XX in daily doses of 15, 30 and 60 mg p.o. and piroxicam in a daily dose of 20 mg p.o. in patients with rheumatoid arthritis. Data on file, Boehringer Ingelheim, Dr. Karl Thomae GmbH, Biberach/Riss, Germany, 1992.

   • Google Scholar
4. • Lund B
   • Distel M
   • Bluhmki E
   A doubleblind, placebo-cointrolled study of three different doses of meloxicam in patients with osteoarthritisof the knee.
   Scand J Rheumatol. 1994; (Abstract no. 117)
   • Google Scholar
5. • Linden B
   • Distel M
   • Bluhmki E
   A double-blind randomised comparison of meloxicam and piroxicam in patients with osteo-arthritis of the hip.
   Scand. J. Rheumatol. 1994; (Abstract no. 182)
   • Google Scholar
6. • Stei P
   • Püschner H
   Intramuscular tolerance of meloxicam compraed to piroxicam and diclofenac in rabbits.
   Scand J Rheumatol. 1994; (Abstract no. 109)
   • Google Scholar
7. • Engelhardt G
   Meloxicam inhibits preferentially COX-2.
   Eur J Clin Pharmacol. 1994; 47: A98
   • Google Scholar

8. Engelhardt G, Homma D, Schlegel K, Schnitzler CHR. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent. Inflamm Res. In press.

   • Google Scholar
9. • Patoia L
   • Santucci L
   • Furno P
   • et al.
   Gastrointestinal (GI) tolerability of meloxicam, piroxicam, and placebo by comparison of fecal blood loss (FBL), upper gastrointestinal endoscopy (UE) and symptoms evaluation.
   Rheumatol Eur. 1995; 24 (Abstract no. E258)
   • Google Scholar

10. Narjes H, Nehmiz G, Busch U. Tolerability and pharmacokinetics of meloxicam (UHAC-62 XX) as a single intramuscular injection in ascending doses of 5, 10, 20 and 30 mg in healthy volunteers. Data on file, Boehringer Ingelheim, Dr. Karl Thomae GmbH, Biberach/Riss, Germany, 1990.

    • Google Scholar
11. • Laufen H
    • Leitold M
    The effect of activated charcoal on the bioavailability of piroxicam in man.
    Int J Clin Pharmacol Ther Toxicol. 1986; 24: 48-52
    • PubMed
    • Google Scholar
12. • Nilsen OG
    Clinical pharmacokinetics of tenoxicam.
    Clin Pharmacokin. 1994; 26: 16-43
    • Scopus (80)
    • PubMed
    • Crossref
    • Google Scholar

13. Busch U, Bozler B, Heinzel G, Schmid J. Pharmacokinetics of ¹⁴C labelled UHAC-62 XX (meloxicam) in man. Data on file, Boehringer Ingelheim, Dr. Karl Thomae GmbH, Biberach/Riss, Germany, 1989.

    • Google Scholar

14. Türck D. Dose-proportionality of UH.AC 62 XX (meloxicam) in humans. A review. Data on file, Dr. Karl Thomae GmbH, Biberach/Riss, Germany, 1993.

    • Google Scholar
15. • Engelhardt G
    • Trummlitz G
    Biological activity of the main metabolites of meloxicam.
    Drugs Exp Clin Res. 1990; 16: 53-56
    • PubMed
    • Google Scholar
16. • Valat JP
    • Jacquart F
    Au début de la sciatique intérêt respectif et date de réalisation des examens d'imagerie autres que les radiographies standard. Arguments cliniques qui nécessitent de faire rapidement un diagnostic différentiel.
    Rachis. 1991; 3: 23-26
    • Google Scholar
17. • Vaccarino V
    • Sirtori CR
    • Bufalino L
    Local and systemic tolerability of piroxicam after intramuscular administration in healthy volunteers.
    Curr Ther Res. 1989; 45: 1-13
    • Google Scholar